Tigris Initiates Phase I Cancer Study
Posted on: Friday, 1 February 2008, 12:00 CST
Tigris Pharmaceuticals has initiated a multi-center, Phase I, ascending dose clinical study of aminoflavone pro-drug, AFP-464 for the treatment of cancer. The first patient was dosed in December 2007 and enrollment is ongoing.
The primary objectives of the study are to determine the dose-limiting toxicity and maximum tolerated dose of AFP-464 in patients with advanced solid tumors. The trial is expected to enroll up to approximately 35 patients across two sites in Europe. Results from the trial are expected to be available in early 2009.
Edmundo Muniz, CEO of Tigris, said: "AFP-464 is a first-in-class molecule with the potential to fill a large unmet medical need in the treatment of cancer. This first trial in Europe along with the two US Phase I trials provides us our first opportunity to assess the drug's activity in patients, and to further build on our understanding of the molecule's mechanism of action."
Source: Datamonitor
Related Articles
- American Heart Association Late-Breaking Clinical Trial Report: Tailoring Drug Dose to Heart Failure Patients' Response More Effective
- AEterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program With Cetrorelix in Benign Prostatic Hyperplasia
- AVI BioPharma Announces Commencement of Dosing in Clinical Trial for Duchenne Muscular Dystrophy
- Peregrine's Bavituximab Shows Promising Anti-Viral Activity and Signs of Prolonged Anti-Viral Effect in Single Dose Monotherapy HCV Trial
- First Patient Dosed in Phase 1 Trial of Tanox's TNX-650
- Ecopia Begins Patient Dosing in Cancer Trial
- Avalon Pharmaceuticals Completes First Dosing Cycle on First Patient and Initiates Second Cohort of AVN944 Phase I Clinical Trial in Cancer
- V.I. Technologies Presents Further Analysis of PA-457's Antiviral Activity Following a Single Oral Dose in HIV-Infected Patients, at 3rd International AIDS Society Conference
- BioVex Begins Phase I/II Clinical Trial of ImmunoVEXtrimelan With the Dosing of Malignant Melanoma Patient
- Somaxon Pharmaceuticals Announces Positive Results in a Phase II Dose-Finding Study of Low-Dose Doxepin in Elderly Patients With Primary Sleep Maintenance Insomnia
 |
 |
User Comments (0)
RSS Feeds